Developer docs
API playgroundTry for free, no card

Search company profiles

Valenta Pharm

Full company profile

uuid000mzw8

Namestring
Valenta Pharm
Legal namestring
Акционерное общество «Валента Фармацевтика» (JSC Valenta Pharm)
Company typeenum
Private
Founded yearint
1997
Descriptiontext

Valenta Pharm (AO Valenta Pharm / АО «Валента Фарм») is a Russian pharmaceutical company founded in 1997 and headquartered in Moscow. The company develops, manufactures, and markets both prescription and over-the-counter drugs across multiple therapeutic areas including psychoneurology, gastroenterology, cough and cold, antihistamines, antibacterial therapy, and women's health. It operates one of the largest high-tech pharmaceutical manufacturing facilities in Eastern Europe at its Scientific and Production Complex in Shchyolkovo, Moscow Oblast, producing approximately 100 million packages of finished dosage forms annually, with GMP and GDP certifications covering Russian regulatory standards.

The company's R&D capability covers the full original-drug development lifecycle — from high-potential molecule discovery through preclinical and clinical research to manufacturing and market launch — supplemented by collaborative development partnerships with European and Asian pharmaceutical developers and academic research relationships, including with George Mason University. Its branded portfolio spans flagship OTC assets such as Grammidin® (throat pain), Ingavirin® (antiviral), and the Multiplast® plaster line; prescription neuropsychiatric brands including Phenazepam® and Fenotropil®; antibacterial products such as Dioxidin® and Zitrolid®; the novel anti-inflammatory Atheriksen® (registered for COVID-19 in Russia in 2022); and women's-health and pediatric lines including Duonika®, 9 months, Moistana®, Fertina/Fertifolin, and Krokha lab® baby cosmetics.

Valenta distributes its products through three principal channels: a medical-representative field-sales force that addresses the hospital segment via state tenders under ФЗ-44 and ФЗ-223, key-account relationships with Russian pharmacy chains for OTC distribution, and direct-to-consumer e-commerce through Wildberries, Ozon, and other marketplaces. Operating geography is anchored in Russia, with extension into CIS markets including Kazakhstan, Uzbekistan, Belarus, and Armenia. The company employs between 101 and 250 staff and ranks among the TOP-5 Russian pharmaceutical companies and on Forbes Russia's TOP-20 (2026), with no publicly disclosed ownership structure or external funding.

Short descriptiontext

Russian pharmaceutical company founded in 1997 that develops and manufactures branded prescription and OTC drugs across psychoneurology, gastroenterology, cold and cough, antibacterial, and women's health therapy areas, operating one of Eastern Europe's largest pharma production facilities with annual output of roughly 100 million packages distributed via pharmacy chains, hospital tenders, and online marketplaces.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersMoscow, Russia
HQ citystring
Moscow
HQ countrystring
Russia
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
prescription pharmaceuticals, over-the-counter drugs, original drug development, pharmaceutical manufacturing, GMP certified production
Industry3 codes
PRIMARYHLAIAAAI
Gastroenterology & Hepatology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYCRAOAHAB
OTC Medicines & Consumer Health Products Distribution
SECONDARYCRAOAHAG
Pharmacy Front-End & Sundries Distribution (Health & Wellness, Personal Care, Convenience)
NAICS code4 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Pharmaceutical Preparation Manufacturing325412
  • Drugs and Druggists' Sundries Merchant Wholesalers42421
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Pharmaceuticals
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Prescription Drugs
TypeOne Time License
Description

Sale of prescription pharmaceutical products including neuropsychiatry, gastroenterology, and antibacterial medications to hospitals and healthcare institutions via tender procurement

valentapharm.com
2Over-the-Counter (OTC) Drugs
TypeOne Time License
Description

Sale of non-prescription drugs including cold remedies, antihistamines, and plaster products through pharmacy chains and marketplaces

valentapharm.com
3R&D and Licensing
TypeLicensing Royalties
Description

Collaborative development partnerships with European and Asian developers, with potential for licensing of innovative products

valentapharm.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Operations, Personnel, Marketing or Sales, Technology or R&D, Supply Chain
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 7 records shown
1Grammidin
Description

Brand for sore throat treatment products including Grammidin Neo, Grammidin with anesthetic, and Grammidin children's formulas.

valentapharm.com
+6 more records
Core offering1 text field

Valenta Pharm is a Russian pharmaceutical company that develops, manufactures, and markets prescription and OTC drugs across therapeutic areas including neuropsychiatry, gastroenterology, anti-cold therapy, antibacterial treatment, women's health, and antihistamines. The company operates one of the largest high-tech pharmaceutical production facilities in Eastern Europe, producing approximately 100 million packages of finished dosage forms annually, with full-cycle R&D from preclinical and clinical research through production and market launch.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • TOP-5 Russian pharmaceutical company ranking
+1 more record
Product overview1 text field

Valenta Pharm is a Russian innovative pharmaceutical company founded in 1997, developing and manufacturing both prescription and over-the-counter drugs. The company operates across multiple therapeutic areas including psychoneurology (Феназепам®, Fenotropil®), cough & cold (Граммидин®, Ингавирин®), gastroenterology, antihistamines, and antibacterial therapy (Dioxidin®, Zitrolid®). Its product portfolio also includes medical devices (Multiplast® plasters for antibacterial, retention, corn, and children's use) and women's health products (Duonika®, 9 months, Moistana®, Fertina/Fertifolin). The company also produces baby cosmetics under the Krokha lab® brand. As one of the largest high-tech pharmaceutical manufacturers in Eastern Europe, Valenta Pharm produces approximately 100 million packages of finished medicinal products annually across socially significant pharmacotherapeutic groups.

Product and service15 records
1Grammidin® (Граммидин)
CategoryOver-the-counter drug
Description

Throat pain relief medication, one of the leading brands in the sore throat category in Russia, marketed as an OTC product for consumers.

2Phenazepam® (Феназепам)
CategoryPrescription drug
Description

Bromodihydrochlorophenylbenzodiazepine-based neuropsychiatric prescription medication for anxiety and related conditions.

3Ingavirin® (Ингавирин)
CategoryOver-the-counter drug
Description

Antiviral medicine for treating flu and ARVI in adults and children, sold as an OTC product.

4Atheriksen® (Атериксен)
CategoryPrescription drug
Description

Unique Russian prescription drug for proactive anti-inflammatory therapy; registered in Russia in 2022 for treatment of mild COVID-19 in adults.

5Multiplast® Antibacterial Plasters
CategoryMedical device
Description

Antibacterial plasters for wound care, featuring chlorhexidine bigluconate impregnated pads, for consumer wound care use.

6Multiplast® Retention Plasters
CategoryMedical device
Description

Natural plaster tapes for secure retention of dressings, intended for medical and consumer use.

7Multiplast® Corn Plaster
CategoryMedical device
Description

Plasters intended for treatment of dry corns and callosities, sold to consumers.

8Multiplast® Kids
CategoryMedical device
Description

Children's plasters with hypoallergenic, breathable design and colorful graphics for minor injuries.

9Dioxidin® (Диоксидин)
CategoryPrescription drug
Description

Prescription antibacterial medication active against microorganisms resistant to other antimicrobial agents including antibiotics.

10Zitrolid® (Зитролид)
CategoryPrescription drug
Description

Azithromycin-based (500 mg capsules) prescription antibacterial medication for respiratory, skin, and urinary tract infections.

11Krokha lab® (Кроха lab)
CategoryBaby cosmetics
Description

Professional dermatological cosmetics line for children from first day of life, featuring emollients with vioceramides, bisabolol, and phytosterol.

129 Months (9 месяцев)
CategoryWomen's health products
Description

Line of products for pregnant women, supporting women's health across pregnancy stages.

13Moistana® (Моистана)
CategoryWomen's health products
Description

Hydrating products for women's intimate health, sold to consumers.

14Duonika® (Дуоника)
CategoryPrescription drug
Description

The only drug in the Russian Federation for treatment of nausea and vomiting in pregnant women; prescription product.

15Fertina and Fertifolin
CategoryDietary supplement
Description

Dietary supplements for women's reproductive health containing inositol and folate, for pregnancy planning and reproductive support.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1European and Asian pharmaceutical developers
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Leading foreign developers from Europe and Asia participate in developing new promising products for Valenta's portfolio. Development is conducted according to international quality standards for drug development and manufacturing.

valentapharm.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic research partnership for Atheriksen® drug. Professor Ancha Baranova from George Mason University's School of Systems Biology co-authored the article published in Frontiers in Pharmacology.

3Russian and international medical organizations
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaborations with Russian and foreign organizations distinguished by professionalism and extensive expertise in research and development for creating innovative drugs and technological solutions.

valentapharm.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Russia's largest domestic pharmaceutical manufacturer; produces branded prescription and OTC drugs, operates its own manufacturing, and competes head-to-head with Valenta in neuropsychiatry, antivirals, and OTC categories including tender-driven hospital supply.

TypeDirect peer
Description

Vertically integrated Russian pharmaceutical manufacturer with branded generics and OTC presence across similar therapeutic areas (respiratory, gastroenterology, neurology) and comparable hospital/pharmacy distribution channels.

TypeDirect peer
Description

Russian pharmaceutical manufacturer ranked similarly in domestic top pharma lists with branded generics and OTC in dermatology, respiratory, and women's health; competes with Valenta in pharmacy retail and government tender channels.

TypeDirect peer
Description

Russia-focused OTC consumer health company with a comparable brand-led marketing model (TV, influencer) and category leadership in cough/cold and sore throat, directly competing with Valenta's Grammidin franchise.

TypeBroad incumbent
Description

Global generics and consumer health major with deep established Russian OTC portfolio through its local subsidiary; offers overlapping sore throat, cold/flu, and dermatology lines and competes broadly in the same pharmacy shelves as Valenta.

TypeBroad incumbent
Description

Slovenian-headquartered generics manufacturer with strong Eastern European and CIS distribution; competes with Valenta in prescription generics, gastroenterology, and respiratory categories across shared regional markets.

TypeBroad incumbent
Description

Global pharmaceutical major with established Russian prescription and OTC business; overlaps with Valenta in respiratory, allergy, gastroenterology, and women's health, though multinational presence has been impacted by geopolitical shifts.

8Bayer Consumer Health
TypeBroad incumbent
Description

Multinational OTC and consumer health leader active in Russia with categories (cold/flu, analgesics, dermatology) directly overlapping Valenta's OTC portfolio, including mass-market pharmacy presence.

9Polysan
TypeEmerging player
Description

Russian branded pharmaceutical developer focused on original drugs and anti-infectives; similar R&D-driven original-drug positioning that overlaps with Valenta's branded prescription portfolio and hospital segment.

10Grotex
TypeEmerging player
Description

Russian pharmaceutical manufacturer building branded and OTC presence, especially in women's health and consumer health categories that intersect with Valenta's Duonika, 9 months, and Fertina/Fertifolin lines.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Valenta Pharm

Pharmaceuticalsvalentapharm.com

Russian pharmaceutical company founded in 1997 that develops and manufactures branded prescription and OTC drugs across psychoneurology, gastroenterology, cold and cough, antibacterial, and women's health therapy areas, operating one of Eastern Europe's largest pharma production facilities with annual output of roughly 100 million packages distributed via pharmacy chains, hospital tenders, and online marketplaces.

What Valenta Pharm does

Valenta Pharm (AO Valenta Pharm / АО «Валента Фарм») is a Russian pharmaceutical company founded in 1997 and headquartered in Moscow. The company develops, manufactures, and markets both prescription and over-the-counter drugs across multiple therapeutic areas including psychoneurology, gastroenterology, cough and cold, antihistamines, antibacterial therapy, and women's health. It operates one of the largest high-tech pharmaceutical manufacturing facilities in Eastern Europe at its Scientific and Production Complex in Shchyolkovo, Moscow Oblast, producing approximately 100 million packages of finished dosage forms annually, with GMP and GDP certifications covering Russian regulatory standards.

The company's R&D capability covers the full original-drug development lifecycle — from high-potential molecule discovery through preclinical and clinical research to manufacturing and market launch — supplemented by collaborative development partnerships with European and Asian pharmaceutical developers and academic research relationships, including with George Mason University. Its branded portfolio spans flagship OTC assets such as Grammidin® (throat pain), Ingavirin® (antiviral), and the Multiplast® plaster line; prescription neuropsychiatric brands including Phenazepam® and Fenotropil®; antibacterial products such as Dioxidin® and Zitrolid®; the novel anti-inflammatory Atheriksen® (registered for COVID-19 in Russia in 2022); and women's-health and pediatric lines including Duonika®, 9 months, Moistana®, Fertina/Fertifolin, and Krokha lab® baby cosmetics.

Valenta distributes its products through three principal channels: a medical-representative field-sales force that addresses the hospital segment via state tenders under ФЗ-44 and ФЗ-223, key-account relationships with Russian pharmacy chains for OTC distribution, and direct-to-consumer e-commerce through Wildberries, Ozon, and other marketplaces. Operating geography is anchored in Russia, with extension into CIS markets including Kazakhstan, Uzbekistan, Belarus, and Armenia. The company employs between 101 and 250 staff and ranks among the TOP-5 Russian pharmaceutical companies and on Forbes Russia's TOP-20 (2026), with no publicly disclosed ownership structure or external funding.

Valenta Pharm firmographics

Firmographics
Name
Valenta Pharm
Legal name
Акционерное общество «Валента Фармацевтика» (JSC Valenta Pharm)
Website
https://valentapharm.com
Company type
Private
Founded year
1997
Operating status
Operating
Headcount range
251–500 employees
Short description
Russian pharmaceutical company founded in 1997 that develops and manufactures branded prescription and OTC drugs across psychoneurology, gastroenterology, cold and cough, antibacterial, and women's health therapy areas, operating one of Eastern Europe's largest pharma production facilities with annual output of roughly 100 million packages distributed via pharmacy chains, hospital tenders, and online marketplaces.
Ownership category
akta.pro rank

Valenta Pharm industry classification

Industry
Product category
Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (42421), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIAAAI
Gastroenterology & Hepatology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYCRAOAHAB
OTC Medicines & Consumer Health Products Distribution
SECONDARYCRAOAHAG
Pharmacy Front-End & Sundries Distribution (Health & Wellness, Personal Care, Convenience)

Keywords

  • Prescription pharmaceuticals
  • Over-the-counter drugs
  • Original drug development
  • Pharmaceutical manufacturing
  • GMP certified production

Where Valenta Pharm is headquartered

Location

Headquarters

HQ city
Moscow
HQ country
Russia
HQ region
Europe

Offices2 records

Markets served

Valenta Pharm business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Operations, Personnel, Marketing or Sales, Technology or R&D, Supply Chain

Revenue model

  1. Prescription Drugs: Sale of prescription pharmaceutical products including neuropsychiatry, gastroenterology, and antibacterial medications to hospitals and healthcare institutions via tender procurement
  2. Over-the-Counter (OTC) Drugs: Sale of non-prescription drugs including cold remedies, antihistamines, and plaster products through pharmacy chains and marketplaces
  3. R&D and Licensing: Collaborative development partnerships with European and Asian developers, with potential for licensing of innovative products

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Valenta Pharm product offering

Product offering

Core offering

Valenta Pharm is a Russian pharmaceutical company that develops, manufactures, and markets prescription and OTC drugs across therapeutic areas including neuropsychiatry, gastroenterology, anti-cold therapy, antibacterial treatment, women's health, and antihistamines. The company operates one of the largest high-tech pharmaceutical production facilities in Eastern Europe, producing approximately 100 million packages of finished dosage forms annually, with full-cycle R&D from preclinical and clinical research through production and market launch.

Product overview

Valenta Pharm is a Russian innovative pharmaceutical company founded in 1997, developing and manufacturing both prescription and over-the-counter drugs. The company operates across multiple therapeutic areas including psychoneurology (Феназепам®, Fenotropil®), cough & cold (Граммидин®, Ингавирин®), gastroenterology, antihistamines, and antibacterial therapy (Dioxidin®, Zitrolid®). Its product portfolio also includes medical devices (Multiplast® plasters for antibacterial, retention, corn, and children's use) and women's health products (Duonika®, 9 months, Moistana®, Fertina/Fertifolin). The company also produces baby cosmetics under the Krokha lab® brand. As one of the largest high-tech pharmaceutical manufacturers in Eastern Europe, Valenta Pharm produces approximately 100 million packages of finished medicinal products annually across socially significant pharmacotherapeutic groups.

Differentiator

Problem solved

Functional benefit

Brands

  • Grammidin: Brand for sore throat treatment products including Grammidin Neo, Grammidin with anesthetic, and Grammidin children's formulas.
  • Multiplast
  • Fenazepam
  • Krokha Lab
  • 9 months
  • Duonika
  • Fertina and Fertifolin

Products and services

  • Grammidin® (Граммидин) Throat pain relief medication, one of the leading brands in the sore throat category in Russia, marketed as an OTC product for consumers.
  • Phenazepam® (Феназепам) Bromodihydrochlorophenylbenzodiazepine-based neuropsychiatric prescription medication for anxiety and related conditions.
  • Ingavirin® (Ингавирин) Antiviral medicine for treating flu and ARVI in adults and children, sold as an OTC product.
  • Atheriksen® (Атериксен) Unique Russian prescription drug for proactive anti-inflammatory therapy; registered in Russia in 2022 for treatment of mild COVID-19 in adults.
  • Multiplast® Antibacterial Plasters Antibacterial plasters for wound care, featuring chlorhexidine bigluconate impregnated pads, for consumer wound care use.
  • Multiplast® Retention Plasters Natural plaster tapes for secure retention of dressings, intended for medical and consumer use.
  • Multiplast® Corn Plaster Plasters intended for treatment of dry corns and callosities, sold to consumers.
  • Multiplast® Kids Children's plasters with hypoallergenic, breathable design and colorful graphics for minor injuries.
  • Dioxidin® (Диоксидин) Prescription antibacterial medication active against microorganisms resistant to other antimicrobial agents including antibiotics.
  • Zitrolid® (Зитролид) Azithromycin-based (500 mg capsules) prescription antibacterial medication for respiratory, skin, and urinary tract infections.
  • Krokha lab® (Кроха lab) Professional dermatological cosmetics line for children from first day of life, featuring emollients with vioceramides, bisabolol, and phytosterol.
  • 9 Months (9 месяцев) Line of products for pregnant women, supporting women's health across pregnancy stages.
  • Moistana® (Моистана) Hydrating products for women's intimate health, sold to consumers.
  • Duonika® (Дуоника) The only drug in the Russian Federation for treatment of nausea and vomiting in pregnant women; prescription product.
  • Fertina and Fertifolin Dietary supplements for women's reproductive health containing inositol and folate, for pregnancy planning and reproductive support.

Quantifiable outcome

  • TOP-5 Russian pharmaceutical company ranking
  • +1 more outcomes

Companies that use Valenta Pharm

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Valenta Pharm technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Valenta Pharm partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • European and Asian pharmaceutical developerscoreStrategic or Co-development PartnerLeading foreign developers from Europe and Asia participate in developing new promising products for Valenta's portfolio. Development is conducted according to international quality standards for drug development and manufacturing.
  • George Mason University (USA) - Ancha BaranovacoreStrategic or Co-development PartnerAcademic research partnership for Atheriksen® drug. Professor Ancha Baranova from George Mason University's School of Systems Biology co-authored the article published in Frontiers in Pharmacology.
  • Russian and international medical organizationscoreStrategic or Co-development PartnerCollaborations with Russian and foreign organizations distinguished by professionalism and extensive expertise in research and development for creating innovative drugs and technological solutions.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Valenta Pharm competitors and assessment

Company assessment

Direct peers

  • Pharmstandard: Russia's largest domestic pharmaceutical manufacturer; produces branded prescription and OTC drugs, operates its own manufacturing, and competes head-to-head with Valenta in neuropsychiatry, antivirals, and OTC categories including tender-driven hospital supply.
  • Vertex (Veropharm): Vertically integrated Russian pharmaceutical manufacturer with branded generics and OTC presence across similar therapeutic areas (respiratory, gastroenterology, neurology) and comparable hospital/pharmacy distribution channels.
  • Akrikhin: Russian pharmaceutical manufacturer ranked similarly in domestic top pharma lists with branded generics and OTC in dermatology, respiratory, and women's health; competes with Valenta in pharmacy retail and government tender channels.
  • OTCPharm: Russia-focused OTC consumer health company with a comparable brand-led marketing model (TV, influencer) and category leadership in cough/cold and sore throat, directly competing with Valenta's Grammidin franchise.

Broad incumbents

  • STADA Arzneimittel AG: Global generics and consumer health major with deep established Russian OTC portfolio through its local subsidiary; offers overlapping sore throat, cold/flu, and dermatology lines and competes broadly in the same pharmacy shelves as Valenta.
  • KRKA: Slovenian-headquartered generics manufacturer with strong Eastern European and CIS distribution; competes with Valenta in prescription generics, gastroenterology, and respiratory categories across shared regional markets.
  • Sanofi: Global pharmaceutical major with established Russian prescription and OTC business; overlaps with Valenta in respiratory, allergy, gastroenterology, and women's health, though multinational presence has been impacted by geopolitical shifts.
  • Bayer Consumer Health: Multinational OTC and consumer health leader active in Russia with categories (cold/flu, analgesics, dermatology) directly overlapping Valenta's OTC portfolio, including mass-market pharmacy presence.

Emerging players

  • Polysan: Russian branded pharmaceutical developer focused on original drugs and anti-infectives; similar R&D-driven original-drug positioning that overlaps with Valenta's branded prescription portfolio and hospital segment.
  • Grotex: Russian pharmaceutical manufacturer building branded and OTC presence, especially in women's health and consumer health categories that intersect with Valenta's Duonika, 9 months, and Fertina/Fertifolin lines.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Valenta Pharm social profiles

Digital presence

Valenta Pharm compliance and trust

Trust signal

Compliance2 records

Valenta Pharm financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Valenta Pharm leadership team

Management profile

Number of profiles

Profiles6 records

Valenta Pharm funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Valenta Pharm M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Valenta Pharm

What does Valenta Pharm do?

Valenta Pharm is a Russian pharmaceutical company that develops, manufactures, and markets prescription and OTC drugs across therapeutic areas including neuropsychiatry, gastroenterology, anti-cold therapy, antibacterial treatment, women's health, and antihistamines. The company operates one of the largest high-tech pharmaceutical production facilities in Eastern Europe, producing approximately 100 million packages of finished dosage forms annually, with full-cycle R&D from preclinical and clinical research through production and market launch.

Is Valenta Pharm a public or private company?

Valenta Pharm is a private company. It is classified as unknown and is currently operating.

When was Valenta Pharm founded?

Valenta Pharm was founded in 1997. It employs 251 to 500 people.

Where is Valenta Pharm based?

Valenta Pharm is headquartered in Moscow, Russia, in the Europe region.

How does Valenta Pharm make money?

Three revenue lines are on record. Prescription Drugs are the primary driver. The others are over-the-Counter (OTC) Drugs and R&D and Licensing.

Who are Valenta Pharm's main competitors?

Direct peers on record are Pharmstandard, Vertex (Veropharm), Akrikhin and OTCPharm. Broad incumbents are STADA Arzneimittel AG, KRKA, Sanofi and Bayer Consumer Health. Emerging players are Polysan and Grotex.

Does Valenta Pharm have an API?

No public API is recorded for Valenta Pharm.

What industry is Valenta Pharm in?

Valenta Pharm's product category is Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAI, Gastroenterology & Hepatology Pharmaceuticals, with a secondary code of CRAOAHAB, OTC Medicines & Consumer Health Products Distribution. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals